Proactive Investors - Run By Investors For Investors

Collagen Solutions makes good progress in "advancing and improving" sales pipeline

The supplier, developer and manufacturer of medical-grade collagen and tissue components said it closed eight new deals compared with two in the same period last year
sales pipeline graphic
The deal flow has improved markedly over the past 12 months

Collagen Solutions PLC (LON:COS) said it made good progress in the first half “advancing and improving” its sales pipeline.

The supplier, developer and manufacturer of medical-grade collagen and tissue components said it closed eight new deals compared with two in the same period last year.  

READ: Collagen Solutions looking ahead to busy second half

In a busy six months to September 30, the company completed patient assessments with eight-year follow up data for our ChondroMimetic cartilage scaffold.

It also relocated its US headquarters to Minneapolis, where it now shares a base with the R&D and commercial teams.

In China it has received import clearance for its biomaterials and achieved its first customer supply agreement.

Grants aid research effort

The research effort will benefit from grant funding of £884,000 (€1mln). Its two Horizon 2020 programmes are related to cell-based tissue regeneration techniques and a collagen-based drug delivery system for the treatment of Parkinson's disease.

Turning to the financials, revenue was flat year on year at £1.86mln, while the company posted an operating loss of £960,000 for the period; not uncommon for a business at this stage of its commercial development.

READ: Collagen Solutions assesses last patient in ChondroMimetic trial

More importantly, Collagen is well finance with £6.74mln in the bank at the period-end.

“The board remains confident of the company increasing shareholder value over the long term whilst mindful of revenue timing with some customers over the next period,” said chief executive Jamal Rushdy.

“We are highly focused in managing through these challenges and are confident of executing on our sales pipeline, hitting key milestones in 2018 and the long term prospects for the company."

View full COS profile View Profile

Collagen Solutions PLC Timeline

Related Articles

test tubes filled with blood
November 02 2017
In all, 116 of the 200 patients with the life-threatening auto-immune disease have been through the 52-week process looking at the efficacy of Lupuzor
newspaper with word cancer magnified
July 11 2017
"In our view, the potential for SCIB1 [Scancell's skin cancer treatment], as already demonstrated by the survival data, is remarkable," said one broker recently
worried man on bed
October 16 2017
“We are delighted by the results of this new survey, which not only reinforce the potential of MED2002 identified in our two earlier surveys but provide some important additional insights”

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use